DOD Pancreatic Cancer, Translational Research Partnership Award
ID: 353864Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353864
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Pancreatic Cancer Translational Research Partnership Award, aimed at fostering collaborations between clinician investigators and research scientists to advance pancreatic cancer research. This grant encourages innovative partnerships to tackle significant challenges in pancreatic cancer, focusing on areas such as early detection, therapeutic development, and understanding the disease's biology, with an emphasis on addressing health disparities and metabolic disruptions. The total funding available for this initiative is $4.8 million, with an expected four awards, each potentially funding up to $750,000. Interested applicants must submit a pre-application by June 28, 2024, followed by full applications due by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524PCARPTRPA_GG.pdf
    The Department of Defense (DOD) has issued a funding opportunity for the FY24 Pancreatic Cancer Translational Research Partnership Award under the Congressionally Directed Medical Research Programs. The initiative aims to support impactful research aimed at reducing the burden of pancreatic cancer among military personnel, veterans, and the general public, with a focus on early detection, therapeutic development, and understanding the disease’s biology. The total available funding for FY24 is $15 million, with significant collaboration encouraged between clinician investigators and research scientists. Applicants must address specific focus areas, such as health disparities, metabolic disruptions, and oncogenic signaling in their proposals. The application process includes a two-step submission: a pre-application due by June 28, 2024, followed by full applications due by October 3, 2024. Each proposal must demonstrate the potential for significant clinical impact and collaboration while adhering to rigorous scientific standards. Awards may fund up to $750,000 but involve separate reports for each Principal Investigator (PI). Overall, this funding opportunity emphasizes collaborative approaches in tackling critical challenges in pancreatic cancer research.
    Similar Opportunities
    Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Comprehensive Partnerships to Advance Cancer Health (CPACH) (U54 Clinical Trial Optional)" aimed at fostering long-term partnerships between Resource Limited Institutions (RLIs) and NCI-designated Cancer Centers (CCs). This initiative seeks to enhance cancer research by addressing disparities in cancer outcomes and promoting outreach and engagement across diverse populations. The program anticipates awarding approximately 12 cooperative agreements, with a minimum funding amount of $850,000, and key deadlines include an estimated synopsis close date of January 16, 2026, and an expected award date of September 1, 2026. For further inquiries, interested applicants can contact Dr. Sandra San Miguel-Majors at 240-276-5977 or via email at ncicpachU54@mail.nih.gov.
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Novel approaches to support therapeutic development in ultra-rare cancers
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "Novel approaches to support therapeutic development in ultra-rare cancers," aimed at exploring innovative methods to enhance therapeutic development for these specific cancer types. This initiative is particularly focused on small businesses, which are encouraged to apply for this cooperative agreement that falls under the discretionary category of funding. The program is significant as it addresses the critical need for advancements in treatment options for ultra-rare cancers, which often lack sufficient research and development support. Interested applicants can reach out to Patrick Johnson, Grants Management Specialist, at patrick.johnson@fda.hhs.gov or call 301-796-0154 for further information. The expected number of awards is two, with no cost-sharing requirement, and the opportunity is set for the fiscal year 2026.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This funding aims to support innovative projects that develop technologies for analyzing and managing biospecimens in cancer research and clinical care, with a focus on proof-of-concept studies that demonstrate feasibility in areas such as cancer biology, early detection, and health disparities. The total estimated program funding is $4.7 million, with individual awards ranging from $50,000 to $150,000, and approximately 17 awards are expected to be made. Interested applicants can reach out to Dr. Kelly Crotty at Kelly.crotty@nih.gov or by phone at 240-255-0917 for further information, with applications due by April 10, 2026.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Metastasis Research Network (U54 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Metastasis Research Network (U54 Clinical Trial Not Allowed), aimed at advancing research on cancer metastasis through the establishment of specialized centers. Applicants are required to propose a cohesive scientific theme supported by two or three interdisciplinary research projects that utilize integrative system-level approaches to understand the complexities of metastasis, including factors such as early dissemination and cellular responses to therapies. This initiative is crucial for enhancing our understanding of metastasis as a systemic issue across various cancer types, including rare and pediatric cancers. The total estimated funding for this program is $6.8 million, with individual awards capped at $1.7 million, and the application deadline is expected to close on May 15, 2026. For further inquiries, interested parties can contact Joanna M. Watson, Ph.D., at 240-276-6206 or via email at watsonjo@mail.nih.gov.
    Critical Path Public Private Partnerships Clinical Trials Optional
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a grant opportunity titled "Critical Path Public Private Partnerships Clinical Trials Optional," aimed at supporting the continuation of existing consortia groups established by the Critical Path Institute. This initiative seeks applications to manage and maintain these groups, fostering innovative projects in research, education, and outreach to enhance drug product innovation and accelerate the development of therapeutics. The grant, which has an award ceiling and floor of $20 million, is expected to result in one award, with applications being accepted for the fiscal year 2024. Interested applicants can contact Terrin Brown at terrin.brown@fda.hhs.gov or (240) 402-7610 for further information.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.